CompletedPhase 2NCT00128882
Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Aarhus
- Principal Investigator
- Mimi Kjaersgaard, MDUniversity of Aarhus, Clinical Institute, Department of Pediatrics
- Intervention
- Anti-D(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 1-14 years · All sexes
- Timeline
- 2004 – 2008
Study locations (17)
- Aalborg University Hospital, Department of Pediatrics, Aalborg, Denmark
- Skejby Hospital, Aarhus University Hospital, Department of Pediatrics, Aarhus N, Denmark
- Amager Hospital, Department of Pediatrics, Copenhagen S, Denmark
- Rigshospitalet, Copenhagen University Hospital, Pediatric Clinic II, Copenhagen Ø, Denmark
- Esbjerg Hospital, Department of Pediatrics, Esbjerg, Denmark
- Gentofte Hospital, Department of Pediatrics, Gentofte Municipality, Denmark
- Herning Hospital, Department of Pediatrics, Herning, Denmark
- Hjoerring Hospital, Department of Pediatrics, Hjørring, Denmark
- Holbæk Hospital, Department of Pediatrics, Holbæk, Denmark
- Hvidovre Hospital, Department of Pediatrics, Hvidovre, Denmark
- Kolding Hospital Department of Pediatrics, Kolding, Denmark
- Nykøbing F, Department of Pediatrics, Nykøbing Falster, Denmark
- Næstved Hospital, Department of Pediatrics, Næstved, Denmark
- Odense University Hospital, Odense C, Denmark
- Randers Hospital, Department of Pediatrics, Randers, Denmark
- +2 more locations on ClinicalTrials.gov
Collaborators
Kjaersgaard, Mimi, M.D.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00128882 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation